Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curanex PharmaceuticalsCURX +7.43%12 Return-on-Tangible-Equity is -130.58% as of Mar. 2026. GuruFocus rates CURX with a GF Score™ of 12/100. Among 1,199 Biotechnology companies, Curanex Pharmaceuticals ranks worse than 73.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Curanex Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was $-12.60 Mil. Curanex Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $9.65 Mil. Therefore, Curanex Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -130.58%.
The historical rank and industry rank for Curanex Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
CURX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -200 Med: -100.35 Max: -54.29
Current: -105.62
During the past 4 years, Curanex Pharmaceuticals's highest Return-on-Tangible-Equity was -54.29%. The lowest was -200.00%. And the median was -100.35%.
CURX's Return-on-Tangible-Equity is ranked worse than 73.73% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs CURX: -105.62
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Curanex Pharmaceuticals Return-on-Tangible-Equity Related Terms
Curanex Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Curanex Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURX vs DRMA, NCNA, CELZ: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Curanex Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curanex Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Curanex Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -130.58% mean?
Curanex Pharmaceuticals (CURX) has a Return-on-Tangible-Equity of -130.58% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Curanex Pharmaceuticals and its competitors. According to the industry distribution chart, Curanex Pharmaceuticals ranks #884 out of 1199 companies in the Biotechnology industry, placing it in the top 73.7%.
Is Curanex Pharmaceuticals' Return-on-Tangible-Equity too high?
Curanex Pharmaceuticals' current Return-on-Tangible-Equity is -130.58%. Based on the distribution chart, Curanex Pharmaceuticals ranks #884 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' Return-on-Tangible-Equity compare to DRMA and NCNA?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #884 out of 1199 companies for Return-on-Tangible-Equity. This places Curanex Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Curanex Pharmaceuticals and its competitors. Curanex Pharmaceuticals's current Return-on-Tangible-Equity is -130.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current Return-on-Tangible-Equity of -130.58%. The current Return-on-Tangible-Equity is -130.58%. Curanex Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current Return-on-Tangible-Equity is -130.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score
Get the complete analysis for CURX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURX has been successfully added to your 
